Loading clinical trials...
Loading clinical trials...
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
Conditions
Interventions
BGB-B2033
Tislelizumab
+1 more
Locations
20
United States
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh)
Pittsburgh, Pennsylvania, United States
Scri Oncology Partners
Nashville, Tennessee, United States
Anhui Provincial Hospital
Hefei, Anhui, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Start Date
July 23, 2024
Primary Completion Date
October 30, 2026
Completion Date
December 31, 2026
Last Updated
April 17, 2026
NCT06811116
NCT06066138
NCT03937830
NCT07405086
NCT02028949
NCT04828486
Lead Sponsor
BeOne Medicines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions